Neuronetics Prepares for Third Quarter 2024 Financial Disclosure
Neuronetics, Inc. (NASDAQ: STIM), a notable name in the medical technology sphere, is gearing up to share its financial and operational highlights for the third quarter of 2024. This disclosure is scheduled to occur just before the market opens on an upcoming Tuesday.
Conference Call to Discuss Results
On the day of the announcement, the company will host a conference call at 8:30 a.m. Eastern Time. This call will allow shareholders and interested parties to gain insights into the company's performance and future direction. The event is expected to provide an engaging platform for the executives to explain the results in detail.
About Neuronetics and Its Mission
Neuronetics stands at the forefront of the neuroscience industry, passionately believing that mental health deserves the same attention and care as physical health. Known for its innovative NeuroStar Advanced Therapy for Mental Health, Neuronetics is actively changing how patients and healthcare providers perceive treatment options in this critical area.
NeuroStar Advanced Therapy’s Impact
NeuroStar is a pioneering, non-drug, non-invasive therapy designed specifically for individuals battling neurohealth issues. This advanced treatment option is particularly beneficial for patients suffering from Major Depressive Disorder (MDD) when conventional medications have proven ineffective. NeuroStar also addresses anxiety symptoms associated with depressive episodes and is approved for adults and adolescents aged 15-21.
Transforming Lives Through Innovation
With over 6.6 million treatments administered, NeuroStar Advanced Therapy has established itself as a leader in the TMS treatment space for MDD. The commitment of Neuronetics is evident in its dedication to enhancing patient outcomes and improving overall quality of life through its groundbreaking technologies.
Safety and Prescribing Information
As with any medical treatment, safety and efficacy are paramount. Neuronetics prioritizes providing comprehensive safety and prescribing information to ensure that patients, providers, and stakeholders are well-informed about NeuroStar and its applications.
Getting In Touch
For investors or media inquiries, Neuronetics has made it clear how to reach out. Mike Vallie and Mark Klausner from ICR Healthcare are available for investor communication at 443-213-0499, while the media can contact EvolveMKD directly at 646-517-4220.
Frequently Asked Questions
What is the purpose of the conference call?
The conference call is designed to provide a detailed overview of Neuronetics' financial and operational performance during the third quarter.
How can I join the conference call?
Participants are encouraged to register and join the call 10 minutes prior to the scheduled start time for the best experience.
What is NeuroStar Advanced Therapy?
NeuroStar is a non-invasive, non-drug treatment aimed at improving the quality of life for patients suffering from neurohealth conditions like depression and anxiety.
Who can benefit from NeuroStar treatment?
Adults and adolescents aged 15-21 suffering from Major Depressive Disorder (MDD) can benefit from NeuroStar treatment, especially those who haven't found relief through traditional medications.
How long has NeuroStar been in use?
NeuroStar Advanced Therapy has been widely adopted, with over 6.6 million treatments delivered, affirming its effectiveness as a leading solution in the mental health field.
